Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
Frontiers in Plant Science
|
December 22, 2025
Drought stress-induced physiological and molecular changes in strawberries: an integrated transcriptomic and metabolomic perspective
Huimin Qiu, Tiao Ning, Huilan Ma, et al.
Frontiers in Microbiology
|
January 27, 2025
Effects of combined inoculation of arbuscular mycorrhizal fungi and plant growth-promoting rhizosphere bacteria on seedling growth and rhizosphere microecology
Wanli Zeng, Dan Xiang, Xuemei Li, et al.
Oncogene
|
March 8, 2025
ROS-ATM-CHK2 axis stabilizes HIF-1α and promotes tumor angiogenesis in hypoxic microenvironment
Ming Bai, Pengzhi Xu, Rong Cheng, et al.
Journal of Cancer Research and Therapeutics
|
February 10, 2021
Chinese expert consensus workshop report: Guideline for permanent iodine-125 seeds implantation of primary and metastatic lung tumors (2020 edition)
Fujun Zhang, Junjie Wang, Jinhe Guo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 22, 2025
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial
Xinyu Wu, Rui Wan, Lin Wu, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 29, 2024
Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer
Heming Li, Yang-Zhuangzhuang Zhu, Lu Xu, et al.
Eclinicalmedicine
|
July 11, 2022
A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
Kexue Deng, Lu Wang, Yuchan Liu, et al.
Signal Transduction and Targeted Therapy
|
February 2, 2026
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial
Fan Zhang, Zhendong Zheng, Hongmei Zhang, et al.
The Lancet. Respiratory Medicine
|
June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Ziming Li, Xiaomin Dang, Dingzhi Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 9, 2025
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study
Lin Wu, Junling Li, Chong-Rui Xu, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
Frontiers in Plant Science
|
December 22, 2025
Drought stress-induced physiological and molecular changes in strawberries: an integrated transcriptomic and metabolomic perspective
Huimin Qiu, Tiao Ning, Huilan Ma, et al.
Frontiers in Microbiology
|
January 27, 2025
Effects of combined inoculation of arbuscular mycorrhizal fungi and plant growth-promoting rhizosphere bacteria on seedling growth and rhizosphere microecology
Wanli Zeng, Dan Xiang, Xuemei Li, et al.
Oncogene
|
March 8, 2025
ROS-ATM-CHK2 axis stabilizes HIF-1α and promotes tumor angiogenesis in hypoxic microenvironment
Ming Bai, Pengzhi Xu, Rong Cheng, et al.
Journal of Cancer Research and Therapeutics
|
February 10, 2021
Chinese expert consensus workshop report: Guideline for permanent iodine-125 seeds implantation of primary and metastatic lung tumors (2020 edition)
Fujun Zhang, Junjie Wang, Jinhe Guo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 22, 2025
Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial
Xinyu Wu, Rui Wan, Lin Wu, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 29, 2024
Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer
Heming Li, Yang-Zhuangzhuang Zhu, Lu Xu, et al.
Eclinicalmedicine
|
July 11, 2022
A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
Kexue Deng, Lu Wang, Yuchan Liu, et al.
Signal Transduction and Targeted Therapy
|
February 2, 2026
First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial
Fan Zhang, Zhendong Zheng, Hongmei Zhang, et al.
The Lancet. Respiratory Medicine
|
June 13, 2024
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
Ziming Li, Xiaomin Dang, Dingzhi Huang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 9, 2025
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study
Lin Wu, Junling Li, Chong-Rui Xu, et al.
Page
of 9